AnaptysBio Inc (ANAB) Shares Sold by Partner Fund Management L.P.

Partner Fund Management L.P. lowered its stake in shares of AnaptysBio Inc (NASDAQ:ANAB) by 42.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 605,345 shares of the biotechnology company’s stock after selling 449,016 shares during the quarter. Partner Fund Management L.P. owned about 2.26% of AnaptysBio worth $38,615,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ANAB. FMR LLC increased its position in AnaptysBio by 11.7% during the 3rd quarter. FMR LLC now owns 3,935,467 shares of the biotechnology company’s stock worth $392,642,000 after purchasing an additional 410,918 shares in the last quarter. Janus Henderson Group PLC increased its position in AnaptysBio by 11.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,143,155 shares of the biotechnology company’s stock worth $313,592,000 after purchasing an additional 312,833 shares in the last quarter. Vanguard Group Inc. increased its position in AnaptysBio by 20.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,851,930 shares of the biotechnology company’s stock worth $184,767,000 after purchasing an additional 308,517 shares in the last quarter. Vanguard Group Inc increased its position in AnaptysBio by 20.0% during the 3rd quarter. Vanguard Group Inc now owns 1,851,930 shares of the biotechnology company’s stock worth $184,767,000 after purchasing an additional 308,517 shares in the last quarter. Finally, BlackRock Inc. increased its position in AnaptysBio by 11.7% during the 4th quarter. BlackRock Inc. now owns 1,816,825 shares of the biotechnology company’s stock worth $115,894,000 after purchasing an additional 189,685 shares in the last quarter.

ANAB has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of AnaptysBio from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. Cantor Fitzgerald reissued a “buy” rating and set a $140.00 target price on shares of AnaptysBio in a research report on Wednesday, February 27th. JPMorgan Chase & Co. initiated coverage on shares of AnaptysBio in a research report on Wednesday, November 21st. They set an “overweight” rating and a $115.00 target price for the company. SunTrust Banks dropped their target price on shares of AnaptysBio to $125.00 and set a “buy” rating for the company in a research report on Friday, January 18th. Finally, Wedbush reaffirmed an “outperform” rating on shares of AnaptysBio in a research report on Friday, March 1st. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $123.67.

NASDAQ:ANAB traded up $1.99 during trading hours on Monday, hitting $73.90. The stock had a trading volume of 1,332 shares, compared to its average volume of 273,890. AnaptysBio Inc has a 1-year low of $54.26 and a 1-year high of $122.48. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -48.21 and a beta of 2.30.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 28th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.27. On average, equities research analysts anticipate that AnaptysBio Inc will post -2.75 EPS for the current year.

In other AnaptysBio news, insider Marco Londei sold 19,075 shares of the stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $69.88, for a total value of $1,332,961.00. Following the completion of the sale, the insider now owns 22,377 shares of the company’s stock, valued at $1,563,704.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Hamza Suria sold 40,000 shares of the stock in a transaction that occurred on Monday, January 14th. The shares were sold at an average price of $70.79, for a total value of $2,831,600.00. Following the transaction, the chief executive officer now owns 70,064 shares of the company’s stock, valued at $4,959,830.56. The disclosure for this sale can be found here. 20.80% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “AnaptysBio Inc (ANAB) Shares Sold by Partner Fund Management L.P.” was originally reported by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.wkrb13.com/2019/03/18/anaptysbio-inc-anab-shares-sold-by-partner-fund-management-l-p.html.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Featured Article: How Do You Calculate Return on Investment (ROI)?

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.